Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 31c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. LMT
9. SPY
10. SBUX

Go back to Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 31c

Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results

August 2, 2017 4:01 PM EDT

WASHINGTON, Aug. 2, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced financial and operational results for the second quarter ended June 30, 2017.

"During the second quarter of 2017, we advanced our company growth strategy and delivered strong operational and financial results," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO.

Key Highlights:

Total net product sales from HETLIOZ® and Fanapt® were $42.1 million during the second quarter of 2017, a 12% increase compared to $37.4 million in the first quarter of 2017 and a 17% increase compared to $36.0 million in the second... More